Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal?
Author:
- 1 April 2013
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 72 (suppl 2) , ii124-ii127
Abstract
Biological agents targeting tumour necrosis factor (TNF) have revolutionised the treatment of rheumatoid arthritis (RA) and clinical remission has become a realistic treatment goal. Discontinuing anti-TNF therapy after sustained remission has emerged as an important area of investigation in rheumatology from the risk-benefit point of view, including health economic considerations. However, there is little information as to whether ‘biologic-free remission’ is possible after sustained remission following intensive treatment with TNF inhibitors in RA. European studies such as BeSt and OPTIMA in patients with early RA and Japanese studies such as remission induction by remicade in patients with RA and HONOR in patients with long-standing RA encountered during routine clinical practice have shown that, after a reduction in disease activity to clinical remission or low disease activity by infliximab or adalimumab in combination with methotrexate, patients can successfully remain in clinical remission without TNF inhibitors with no radiological and functional damage progression of articular destruction. Experimental findings in TNF-deficient mouse models suggest that TNF inhibitors may change the disease process of RA and bring about the potential of immunological remission, raising the possibility of a ‘treatment holiday’ of TNF inhibitors after intensive treatment.Keywords
This publication has 18 references indexed in Scilit:
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- Inflammatory bone loss: pathogenesis and therapeutic interventionNature Reviews Drug Discovery, 2012
- T‐cell receptor signaling and the pathogenesis of autoimmune arthritis: insights from mouse and manImmunology & Cell Biology, 2012
- The Pathogenesis of Rheumatoid ArthritisNew England Journal of Medicine, 2011
- Rheumatoid arthritisThe Lancet, 2010
- Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritisArthritis & Rheumatism, 2007
- Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trialArthritis & Rheumatism, 2005
- Very early treatment with infliximab in addition to methotrexate in early, poor‐prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve‐month randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2005
- Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor–mediated arthritisArthritis & Rheumatism, 2004
- Critical Roles for Interleukin 1 and Tumor Necrosis Factor α in Antibody-induced ArthritisJournal of Experimental Medicine, 2002